Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial to Evaluate the Protective Efficacy, Immunogenicity, and Safety of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in People Aged 6 Weeks to 13 Years

NCT06524947 is registered in ClinicalTrials.gov with Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. as lead sponsor.

NCT NCT06524947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06524947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial to Evaluate the Protective Efficacy, Immunogenicity, and Safety of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in People Aged 6 Weeks to 13 Years
Lead sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 27, 2024
Completion date
March 28, 2027
Enrollment
6,600 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute gastroenteropathy due to norovirus